The finder
Pick what you want to change. See who actually measured it.
Every other tool like this gives you a compound and a match score. Those scores are not measured. Ours does not exist. What you get instead is what was actually measured and where: trials in people first with the participant count, then the animal and cell work kept separate, then what people using it report, and the trials that found nothing, counted rather than dropped.
82 of the 444 compounds here have never been through a trial in people. That is worth knowing and it is not a verdict: a molecule nobody can patent has no sponsor to pay for a trial, so a thin human record is usually a fact about money rather than about the compound. Where that is the case, this says so and shows you what does exist.
What are you trying to change?
Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive, so you can see where the evidence is before you choose.
Or start from the compounds
Somebody handed you a stack. What is actually known about it?
Add what you are looking at and you get every outcome those compounds have been measured for in people, and then the longer list of the ones they have not.
Blood pressure
Does it move blood pressure?
Reported in almost every metabolic trial, often as a secondary result nobody advertises.
1,196 people · 23 human studies · 13 compounds
- 608 people4 studies1 found nothing
found nothingThe Nattokinase Atherothrombotic Prevention Study (NAPS, NCT02080520), the only large, long, placebo-controlled Western academic RCT of nattokinase: 265 adults without cardiovascular disease, median age 65.3, 2,000 FU/day for a median of 3 years, with carotid ultrasound every 6 months. No significant difference from...
Clinical Hemorheology and Microcirculation, 2021 · 265 people
Double-blind, placebo-controlled RCT, 178 patients with stable coronary artery disease already taking statins, aspirin or beta-blockers, randomized to nattokinase (3,615 FU/day), red yeast rice, the combination, or placebo for 90 days: nattokinase alone significantly lowered LDL-C versus placebo but not total...
Frontiers in Nutrition, 2024 · 178 people
Randomized, double-blind, placebo-controlled trial, 86 adults with pre-hypertension or stage 1 hypertension (73 completed), 2,000 FU/day for 8 weeks: net change versus placebo of -5.55 mmHg systolic (95% CI -10.5 to -0.57) and -2.84 mmHg diastolic (95% CI -5.33 to -0.33), with a matching fall in plasma renin activity.
Hypertension Research, 2008 · 86 people
- 213 people5 studies3 found nothing
found nothingThe largest and longest diabetes trial here: 192 patients, 40 or 500 mg per day for six months. CRP fell 5.6% and 15.9% versus placebo but not significantly, and there was no significant change in weight, BMI, waist, blood pressure, fasting glucose, HbA1c, insulin, C-peptide, free fatty acids, liver enzymes, uric...
Pharmacological Research, 2016 · 192 people
Eleven healthy obese men, randomised double-blind crossover, 150 mg per day for 30 days. Sleeping and resting metabolic rate fell; muscle AMPK was activated with higher SIRT1 and PGC-1alpha protein and improved mitochondrial respiration on a fatty-acid substrate; intrahepatic lipid, circulating glucose, triglycerides,...
Cell Metabolism, 2011 · 11 people
found nothingTen adults aged 72 on average, open-label, 1 to 2 g per day for four weeks. Peak post-meal glucose fell from 185 to 166 mg/dL (p = .003), three-hour glucose AUC from 469 to 428 (p = .001) and the Matsuda index rose from 3.1 to 3.8 (p = .03). Fasting glucose, weight, blood pressure and lipids were unchanged. Ten...
Journals of Gerontology Series A, 2012 · 10 people
- 184 people2 studies
109 hospitalised patients randomised to tolvaptan or carperitide. Symptoms and plasma BNP improved similarly in both groups. Blood pressure was lower after carperitide, and fewer adverse events such as worsening heart failure and hypotension requiring discontinuation occurred with tolvaptan (p = 0.027).
Journal of Clinical Pharmacology, 2013 · 109 people
75 patients with acute heart failure given 0.0125 micrograms per kilogram per minute of carperitide for 6 hours. Lower baseline plasma ANP (r = -0.35, p = 0.002) and lower vasopressin (r = -0.54, p < 0.001) predicted a larger diuretic response; baseline blood pressure, renal function and prior loop diuretic use did...
ESC Heart Failure, 2022 · 75 people
- 80 people1 study
80 adults with total cholesterol at or above 200 mg/dL and/or LDL at or above 100 mg/dL, in four arms for 6 to 8 weeks: pterostilbene 125 mg twice daily, 50 mg twice daily, 50 mg plus grape extract 100 mg twice daily, or placebo. LDL rose 17.1 mg/dL on pterostilbene monotherapy (p = 0.001), an effect not seen with the...
Evidence-Based Complementary and Alternative Medicine, 2014 · 80 people
- 37 people2 studies2 found nothing
found nothing37 adults aged 40 to 80 with systolic pressure 125 to 160 mmHg, 100 mg (-)-epicatechin a day for 4 weeks in crossover. Flow-mediated dilation: +1.1 percentage points, 95 percent CI -0.1 to 2.3, p = 0.07, not significant. Fasting insulin fell 1.46 mU/L (p = 0.03) and HOMA-IR fell 0.38 (p = 0.04). No change in blood...
American Journal of Clinical Nutrition, 2015 · 37 people
found nothing48 overweight or obese non-smokers aged 20 to 65 with features of metabolic syndrome, 25 mg (-)-epicatechin a day for 2 weeks in crossover. No significant effect on blood pressure, glucose, insulin, HOMA-IR, triglycerides, total, LDL or HDL cholesterol, or oxidised LDL. The authors conclude the cocoa effect cannot be...
American Journal of Clinical Nutrition, 2018 · no headcount in the line
- 36 people1 study
The cost side, in a different indication. 36 patients with acquired aplastic anaemia on danazol monotherapy at 10 mg per kg per day capped at 600 mg. After 6 months HDL cholesterol fell 30 percent and LDL rose 11 percent, with significant changes in left ventricular mass, ejection fraction and diastolic indices. The...
Blood Cells, Molecules and Diseases, 2025 · 36 people
- 23 people1 study1 found nothing
found nothing23 women randomised double-blind to 250 mg of a 10 percent Coleus forskohlii extract twice daily (n equals 7) or placebo (n equals 12) for 12 weeks. No significant differences in fat mass, fat-free mass or body fat percentage. Non-significant trends toward mitigating gains in body mass (p equals 0.10) and scanned mass...
Journal of the International Society of Sports Nutrition, 2005 · 23 people
- 8 people2 studies1 found nothing
The safety-relevant human study, in eight healthy male volunteers given a 60-minute infusion of human galanin at 80 pmol/kg per minute or saline. Galanin lowered supine plasma noradrenaline from 0.84 to 0.33 nmol/L and blunted the noradrenaline response to standing from 1.68 to 0.44 nmol/L, while enhancing the...
The Journal of Clinical Endocrinology and Metabolism, 1995 · 8 people
found nothingThe first human study. Galanin infused for 60 minutes into healthy volunteers at 7.8 pmol/kg per minute (n=4) or 33.2 pmol/kg per minute (n=6). Plasma growth hormone rose from 2.8 to a mean peak of 48.5 mU/L at the high dose and from 2.5 to 23.5 mU/L at the low dose; prolactin rose from 176 to 274 mU/L. No change in...
The Lancet, 1986 · no headcount in the line
- 7 people1 study1 found nothing
found nothing7 heart failure patients on a left ventricular assist device given oral clenbuterol up-titrated to 720 micrograms a day for 3 months. No serious adverse events or arrhythmias, creatine phosphokinase rose in 4 patients. Ejection fraction did not improve and end-diastolic dimension increased; body weight and lean mass...
The Journal of Heart and Lung Transplantation, 2006 · 7 people
- no headcount stated1 study
Small open study: inhaled VIP improved hemodynamics and exercise capacity in primary pulmonary hypertension patients deficient in VIP.
Journal of Clinical Investigation, 2003 · no headcount in the line
- no headcount stated1 study1 found nothing
found nothingRandomised 2:1, 30 overweight or obese adults aged 45 and over, MIB-626 two 500 mg tablets twice daily for 28 days. Body weight fell 1.9 kg (95 percent CI -3.3 to -0.5, P=.008), diastolic blood pressure fell 7.01 mmHg (-13.44 to -0.59, P=.034), total cholesterol fell 26.89 mg/dL (P=.004) and LDL fell 18.73 mg/dL...
Journal of Clinical Endocrinology and Metabolism, 2023 · no headcount in the line
- no headcount stated1 study
266 elderly and older persons assessed over six to eight years, with thymalin and epithalamin applied during the first two to three years. Acute respiratory disease incidence fell 2.0 to 2.4-fold, with reduced clinical ischaemic heart disease, hypertension, deforming osteoarthrosis and osteoporosis against control....
Neuro Endocrinology Letters, 2003 · no headcount in the line
- no headcount stated1 study
Analysis of the 154 strokes in TREAT: 5.0 percent of the darbepoetin group and 2.6 percent of the placebo group. Assignment to darbepoetin was an independent predictor (odds ratio 2.1, 95 percent confidence interval 1.5 to 2.9). The doubling could not be attributed to baseline characteristics or to post-randomisation...
Circulation, 2011 · no headcount in the line
- no headcount stated0 studies
Mouse. Clearing senescent cells, including with ABT-263, worsened pulmonary hypertension in several models. A senolytic harm signal in animals, reported here because the benefit signals in animals are quoted constantly and this one is not.
Circulation, 2023 · no headcount in the line
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
How this is counted
Human studies only. Animal and test-tube work never enters this ranking, because the question you asked was about a person.
A compound is listed for an outcome only when a citation on its own page states that outcome and reports a result for it. Naming it is not enough: a paper that measures testosterone and reports a result about something else does not count as testosterone evidence, which is a mistake this tool made on its first run and no longer makes.
People counts are read out of the study lines themselves and are deliberate undercounts. Where a line states no number, the study still counts as a study and adds nothing to the headcount. Counts are never added across compounds, because the same person can appear in more than one trial.
Ranking is by people measured. That is a fact about the evidence, not a judgement about the compound, and it is the only ordering this site will defend. A compound at the top of a list is the most studied, which is not the same as the best.
Nothing here is advice, and nothing here is a recommendation to take anything.